An EPO biotechnology patent application should be drafted so the original disclosure supports the intended claim scope, enables the skilled person to carry out the invention, preserves amendment positions under Article 123(2), and records the technical effects or technical difficulties that may later matter to inventive step. For antibodies, proteins, nucleic acids, engineered cells, diagnostics and other life-science inventions, the filing should connect structure, function, experimental evidence, sequences and fallback positions from the outset.
For European biotechnology prosecution, a commercially broad claim is useful only if the application as filed supports the breadth, enables the skilled person to carry out the invention, and contains defensible fallback positions. The drafting task is therefore broader than writing claims. It includes preserving explicit basis for later amendments, documenting biological mechanisms and technical effects, preparing sequence disclosure correctly, and anticipating how inventive step will be assessed in a field where a reasonable expectation of success can be decisive.
Article 83 EPC requires the European application to disclose the invention sufficiently clearly and completely for the skilled person to carry it out. In biotechnology, this can make working examples, reproducible protocols, structure-function relationships and the predictability of alternatives especially important.
Article 123(2) EPC prevents later amendments that add subject matter beyond the application as filed. Drafting should therefore make important combinations, alternatives, ranges, sequence variants and fallback positions explicit before filing rather than assuming they can be assembled later.
EPO biotechnology applications should distinguish between the scope the applicant wants commercially and the scope the original disclosure can genuinely support. Article 83 addresses whether the skilled person can perform the claimed invention across the relevant scope, while Article 84 requires the claims to be clear, concise and supported by the description. These requirements interact in practice: very broad functional language can become difficult where the application supplies only a narrow implementation and little technical reasoning for why the broader class should work.
For antibodies, proteins, nucleic acids, engineered cells, vectors, diagnostics, biomarkers and therapeutic uses, the specification should identify the structural and functional features that define the invention, the biological context in which those features matter, representative embodiments, relevant alternatives, and the evidence supporting the intended technical effect.
European prosecution frequently turns on whether a proposed amendment is directly and unambiguously derivable from the application as filed. That makes the original disclosure a strategic asset. If a likely fallback is commercially important, it is safer to disclose it as an identifiable embodiment or combination than to rely on later extraction of isolated features from different passages.
| Drafting issue | What to capture at filing | Later EPO value |
|---|---|---|
| Fallback combinations | Expressly disclose narrower feature combinations and dependent positions | Supports later claim narrowing without manufacturing a new combination |
| Sequence variants | Define variants structurally and functionally, with examples or rationale where available | Supports claim scope and amendment options |
| Ranges and sub-ranges | Disclose meaningful endpoints and preferred intervals | Creates defensible positions for later limitation |
| Optional features | State whether features are optional, preferred or essential | Reduces ambiguity when features are removed or combined later |
| Technical effects | Connect effects to the relevant embodiments or technical features | Helps later problem-solution and inventive-step arguments |
The EPO's 2026 Guidelines contain dedicated antibody guidance. A novel antibody binding a known antigen is not automatically inventive merely because its exact sequence was unpredictable. The Guidelines state that inventive step may be supported by a surprising technical effect, a lack of reasonable expectation of success, technical difficulties in generating or manufacturing the antibody, or a novel functional antibody format.
Drafting should therefore capture more than binding function. Depending on the invention, useful disclosure may include heavy- and light-chain sequences, CDR definitions, epitope information, affinity or potency measurements, selectivity, stability, immunogenicity, therapeutic activity, manufacturing characteristics, functional formats and comparative data against relevant prior-art antibodies.
Where the inventive contribution lies in an unexpected property, the application should record that effect and the evidence supporting it as early as possible. That evidence may later become central to the objective technical problem and inventive-step analysis.
The EPO's current Guidelines state that, in biotechnology, a solution may be obvious where the skilled person would have followed the prior art with a reasonable expectation of success. A mere hope of success is different. If success depends on non-trivial choices or overcoming genuine technical uncertainty, the analysis may point the other way.
The specification should therefore document the technical obstacles that existed before the invention, why the selected approach was not routine, which choices mattered, and what experimental results demonstrate that the approach worked. This is particularly useful for antibody engineering, protein design, gene editing, cell engineering, complex assays, manufacturing processes and biological systems where outcomes are difficult to predict.
Examples are most useful when they establish the relationship between the claimed technical features and the asserted technical effect. Record protocols, controls, comparative examples, relevant assay conditions, reproducibility information and negative results where they help define the invention's actual contribution.
For untested variants, separate demonstrated embodiments from predictions. If the application relies on a technical effect across a broad class, explain the mechanistic or structural reasoning that supports that breadth rather than assuming that one example proves every alternative.
For European patent applications disclosing qualifying nucleotide or amino-acid sequences, the EPO requires sequence listings that comply with WIPO Standard ST.26. The EPO's 2026 Guidelines state that qualifying sequences are filed electronically in XML form and that the SEQ ID numbers in the description should correspond to the sequence listing.
The sequence-listing requirement is not merely a filing-formality issue. Drafting teams should coordinate sequence identifiers, variant definitions, fragments, database references and claim language so that the narrative description, claims and XML listing tell the same technical story. Where sequences are referred to only through database accession numbers, the EPO also provides specific guidance on when a separate sequence listing is or is not required.
Claims to variants, homologues, fragments or functionally defined biological classes should be supported by an intelligible technical boundary. Useful drafting may combine percentage identity, specified residues, conserved motifs, functional tests, biological activity thresholds or structural relationships, depending on the technology.
Avoid using a broad functional label as a substitute for disclosure. The application should explain how members of the class are identified, why the relevant alternatives are expected to work, and where the practical boundary of the class lies.
European biotechnology practice also contains subject-matter rules that can affect claim architecture, including exclusions or limitations relating to certain plant and animal processes, human-body subject matter and other biotechnology-specific categories. The master biotechnology page should remain broad, but an EPO-focused draft should identify any subject-matter constraint early enough to shape the initial claim set and specification.
Where the invention involves therapeutic, diagnostic, microbiological, plant, animal or human biological subject matter, the drafting strategy should separate protectable products, substances, compositions, uses, methods and technical processes in a way that fits the applicable EPC framework.
EPO inventive step is normally assessed using the problem-solution approach. In biotechnology, that makes the connection between the distinguishing technical features and the resulting technical effect particularly important. A specification that clearly records the relevant effect, comparative evidence and technical mechanism can provide a stronger foundation for later formulation of the objective technical problem.
Where the contribution is an unexpected improvement, selection, activity profile, stability advantage, reduced immunogenicity, yield improvement, manufacturability gain or another technical result, preserve the evidence and the technical relationship in the original filing.
A biotechnology application that enters Europe through the PCT should be drafted with EPO amendment and sufficiency principles in mind from the priority filing. The PCT route does not create missing basis later. If the original application omits an important sequence combination, fallback range or technical-effect relationship, the later European phase may not be able to repair that omission.
Use the broader Biotechnology Patent Drafting guide for cross-jurisdiction strategy, the EPO Patent Drafting guide for general European drafting principles, the PCT guide for international filing mechanics, and the EPO Examination Response guide for later prosecution.
European biotechnology drafting is strongest when disclosure depth, sequence information, technical effects and fallback positions are coordinated before filing. The shared featured video provides additional context on patenting technology-driven inventions.
Discuss the biological invention, experimental support, sequence disclosure, claim architecture, target markets and desired protection outcome before filing.
